1. Introduction {#sec1}
===============

The incidence of preterm birth in developed countries has not changed for 40 years and it ranges from 6 to 13%, despite significant advances in perinatal care \[[@B1]\]. Premature birth is one of the major causes of morbidity and mortality in developed countries. However, not all women admitted to the hospital with preterm labor symptoms give birth prematurely. The high cost of caring for these patients should be taken into account \[[@B2]\]. Currently, it is believed that the main cause of premature births is subclinical infection, which leads to premature contractile activity and/or rupture of fetal membranes through different potential mechanisms \[[@B3]--[@B6]\]. Microbiological studies indicate that 25--40% of preterm births may be the result of infection \[[@B7]\]. Perhaps this percentage is higher, because intrauterine infection is difficult to diagnose by conventional methods of identification based on microbiological culture \[[@B8]\].

Asymptomatic infection of the amniotic cavity may initiate a cascade of inflammatory factors that stimulate the production of prostaglandins, which consequently lead to abnormal uterine contractile activity and irreversible changes in the cervix as well as structures of membranes.

Evaluation of preterm labor markers, which induce clinically silent inflammation, may increase the effectiveness of detection and treatment of preterm delivery \[[@B9]\]. For several years, chemokines have been of special interest to researchers because of their likely participation in the initiation of parturition \[[@B10], [@B11]\]. Chemokines are a family of small molecular weight cytokines, which are involved in leukocytes stimulation and chemotactic gradient determining. The increase of the chemokines concentration could be associated not only with infection but also with the mechanism of labor \[[@B12]\]. In our previous pilot study we found significantly lower concentrations of one of the tested chemokine MIP-3*β*/CCL19 in the group of patients who gave birth prematurely, compared to the women demonstrating symptoms of preterm labor but delivered at term \[[@B13]\].

The aim of the present study was to determine the concentration of selected, hitherto practically unexplored, group of chemokines in sera of women with premature birth without clinical signs of infection and patients with threatened preterm delivery.

2. Material and Methods {#sec2}
=======================

The study group consisted of patients who delivered at three Polish tertiary centers: Department of Perinatology of the Medical University of Bialystok, Poland, (recruitment between 2007 and 2013), Department of Obstetrics and Gynecology of District Hospital of Przemysl, Poland, (recruitment between 2009 and 2012), and Department of Obstetrics and Pathology of Pregnancy of Medical University of Lublin, Poland, (recruitment between 2012 and 2013). About 1800, 1500, and 1600 births per year, respectively, took place at these departments. Great proportion of patients admitted to the above mentioned centers from district hospitals, where they were treated with steroids or antibiotics and subsequently gave birth within 72 hours, were excluded from the study (see exclusion criteria below).

The study protocol was approved by the Local Ethical Committee of Medical University of Bialystok, Poland, and an informed consent was obtained from each patient.

Biochemical studies were performed on serum samples from three groups of women: group I---women with preterm birth between the 23rd and the 36th weeks of gestation (62 patients), group II---women with subjective symptoms of threatening preterm delivery (so-called false preterm labor), between the 23rd and the 36th weeks, who delivered at term (47 patients), and group III---patients recruited at term who gave natural birth between the 39th and the 41st weeks of pregnancy (28 patients). The gestational age of all participating women was confirmed by ultrasound examination performed in the first trimester of pregnancy. The diagnosis of preterm labor (group I) was made according to previously established criteria \[[@B13], [@B14]\]. In all these patients, labor started with regular contractions and progressive cervical dilation (*n* = 29) or preterm premature rupture of membranes (pPROM)---(*n* = 33). The diagnosis of pPROM was defined as the presence of vaginal pooling with positive Amnisure test (Qiagen) prior to regular uterine activity.

Exclusion criteria from the study were multiple pregnancy, pregnancy induced hypertension, diabetes, kidney disease (creatinine above 2 mg/dL), and other complications during pregnancy, such as anemia, thrombocytopenia, systemic disease, thrombophlebitis, steroids and antibiotics within 72 hours of blood sampling, cervical incompetence and cervical cerclage, and finally clinical chorioamnionitis (at least one temperature elevation of \>37.8°C, tachycardia, uterine tenderness greater than expected, white blood cell(WBC) count above 18,000, and unpleasant vaginal odor).

10 mL of peripheral blood was collected from each patient. The blood was then centrifuged; serum was separated and frozen at −80°C temperature.

To assess the concentration of chemokines in the blood serum we used a multiplex method, which allows the simultaneous determination of 40 chemokines per sample. Like a traditional sandwich-based ELISA, it uses a pair of specific chemokine antibodies for detection. A capture antibody is first bound to the glass surface. After incubation with the sample, the target chemokine is trapped on the solid surface. A second biotin-labeled detection antibody is then added, which can recognize a different isotope of the target chemokine. The chemokine-antibody-biotin complex is then visualized through the addition of the streptavidin-labeled Cy3 equivalent dye using a laser scanner (GenePix 4100A). Unlike the traditional ELISA, Quantibody products use array format. By arraying multiple chemokine specific capture antibodies onto a glass support, multiplex detection of chemokines in one experiment is made possible.

The sets (Quantibody Array Human Chemokine, RayBiotech Inc.) consist of the following chemokines: CC chemokine ligand 21 (6Ckine/CCL21), protein tyrosine kinase (Axl), betacellulin (BTC), chemokine (C-C Motif) ligand 28 (CCL28), cutaneous T-cell attracting chemokine (CTACK/CCL27), chemokine (C-X-C motif) ligand 16 (CXCL16), epithelial neutrophil-activating protein 78 (ENA-78/CXCL5), eotaxin-3/CCL26, granulocyte chemotactic protein 2 (GCP-2/CXC), growth-regulated protein *α*, *β*, *γ* (GRO*α*/CXCL1, GRO*β*/CXCL2, and GRO*γ*/CXCL3), hemofiltrate cc chemokine 1 (HCC-1/CCL14), hemofiltrate CC chemokine 4 (HCC-4/CCL16), interleukin 9 (IL-9), interleukin 17F (IL-17F), interleukin 18 binding protein (IL18-BPa), interleukin 28A (IL-28A), interleukin 29 (IL-29), interleukin 31 (IL-31), Interferon Inducible Protein 10 (IP-10/CXCL10), Interferon-Inducible T-cell alpha chemoattractant (I-TAC/CXCL11), leukemia inhibitory factor (LIF), ligand for herpesvirus entry mediator (LIGHT/TNFSF14), lymphotactin/XCL1, monocyte chemoattractant protein 2 (MCP-2/CCL8), monocyte chemoattractant protein 3 (MCP-3/CCL7), monocyte chemoattractant protein 4 (MCP-4/CCL13), macrophage-derived chemokine (MDC/CCL22), macrophage migration inhibitory Factor (MIF), macrophage inflammatory protein-3-alfa (MIP-3*α*/CCL20), macrophage inflammatory protein-3-beta (MIP-3*β*/CCL19), myeloid progenitor inhibitory factor 1 (MPIF-1/CCL23), neutrophil-activating peptide 2 (NAP-2/CXCL7), macrophage stimulating protein alpha (MSP*α*), Osteopontin (OPN), pulmonary and activation-regulated chemokine (PARC/CCL18), platelet factor 4 (PF4), stromal cell-derived factor-1 (SDF-1/CXCL12), thymus and activation regulated chemokine (TARC/CCL17), thymus-expressed chemokine (TECK/CCL25), and thymic stromal lymphoprotein (TSLP).

We also performed CRP (C reactive protein) and PCT (procalcitonin) determination. CRP was measured using immunoturbidimetric method with the Multigent CRP Vario assay (detectable range was 0.2--480 mg/L) detected on the ARCHITECT ci4100. PCT was assessed by the use of VIDAS B*·*R*·*A*·*H*·*M*·*S PCT test based on ELFA (enzyme linked fluorescent assay) technology (detectable range was 0.05--200 ng/mL).

Analysis of chemokines concentrations in each group was performed using GraphPad Prism package and STATISTICA 10. The analysis used nonparametric tests, due to rejection of the hypothesis of normal distribution of individual markers in groups (Shapiro-Wilk test). The Kruskal-Wallis test was used to compare the median concentration of chemokines between three distinguished groups, and differences at the significance level 0.05 were the basis for performing multiple comparisons with Dunn\'s test. We also used Kruskal-Wallis test to compare serum concentration of WBC, CRP, and PCT between three groups. The correlation between WBC, CRP, PCT, and serum chemokines concentration was assessed by Spearman rank correlation analysis.

Mann-Whitney-Wilcoxon\'s test was used to compare the median between the groups of patients who delivered before and after 7 days from the onset of signs and between the groups of patients with and without pPROM.

Receiver operating characteristic (ROC) curves were determined for statistically significant results between the groups of preterm labor and false preterm labor. The ROC curve describes the relationship between sensitivity (fraction of true positives) and the value of 1 − specificity (fraction of true negatives). The area under the curve (AUC) indicates the quality of a given characteristic as a classifier and the value of 0.5 indicates randomness of the test.

3. Results {#sec3}
==========

Clinical characteristic of the patients is presented in [Table 1](#tab1){ref-type="table"}. The median values of maternal serum chemokines concentrations in each study group and *P* values are presented in [Table 2](#tab2){ref-type="table"}.

Patients with preterm labor had higher serum concentrations of 3 chemokines: I-TAC, MIP-3*α*, and TARC and lower serum concentration of HCC-4 ([Table 2](#tab2){ref-type="table"}) when compared to patients with threatened preterm labor. We included these chemokines in later analyses and created ROC curves for them, which set the threshold values and allowed predicting the likelihood of preterm delivery with specific sensitivity and specificity (minimal sensitivity was set to 0.7).

The area under the ROC curve for HCC-4 was 0.64, for I-TAC it was 0.68, for MIP-3*α* it was 0.73, and for TARC it was 0.67 ([Figure 1](#fig1){ref-type="fig"}). All field values are satisfactory and indicate the usefulness of these biochemical markers as tools to predict the risk of preterm delivery.

We demonstrated a significantly higher risk of preterm birth when the serum concentration of HCC-4 \< 1285 pg/mL (sens. 0.74, sp. 0.45, *P* = 0.013), I-TAC \> 33.35 pg/mL (sens. 0.73, sp. 0.56, *P* = 0.002), MIP-3*α* \> 3.60 pg/mL (sens. 0.74, sp. 0.50, *P* = 0.019), and TARC \> 44.10 pg/mL (sens. 0.75, sp. 0.57, *P* = 0.003) ([Figure 2](#fig2){ref-type="fig"}).

Diagnostic values of these chemokines are presented in [Table 3](#tab3){ref-type="table"}.

When we compared the serum concentration of chemokines between patients with preterm labor before (*n* = 44) and after (*n* = 18) 7 days from the onset of signs and between patients with pPROM (*n* = 33) and without pPROM (*n* = 29), we did not observe statistically significant differences as to any of the studied chemokines.

We did not find any statistically significant differences when we compared serum concentration of WBC, CRP, and PCT between three groups using Kruskal-Wallis test. Statistically significant correlation, by Spearman rank correlation analysis, was identified only in the group of preterm labor between CRP and TECK: *r* = −0.31; *P* = 0.05 and between WBC and NAP-2: *r* = 0.46; *P* = 0.01.

4. Comment {#sec4}
==========

In our present study, we examined the serum concentration of 40 chemokines in blood serum of pregnant patients and 4 of them were statistically significantly different between the groups of preterm labor and false preterm labor. The concentration of 3 chemokines, that is, I-TAC, MIP-3*α*, and TARC above the cut-off value and HCC-4 below the cut-off value, indicates the risk of preterm delivery.

In our previous work, we compared, among others, the serum concentration of such chemokines as I-TAC, MIP-3*α*, TARC, MIP-3*β*, MDC, and IP-10 between the groups of preterm birth (*n* = 17), false preterm labor (*n* = 13), and term deliveries (*n* = 8) \[[@B13]\]. We did not find statistically significant differences in chemokines I-TAC, MIP-3*α*, and TARC, which were found in the present study. However, this difference occurred in the chemokine MIP-3*β*. It could be due to the smaller number of patients who participated in the previous study. The concentrations of MDC and IP-10 did not show statistically significant differences in both studies.

There are potential explanations for the role of differentially expressed chemokines in the pathophysiology of preterm labor. I-TAC, as a factor of leukocytes migration, attracts active lymphocytes in the place of inflammation. It was found that I-TAC concentration in the amniotic fluid increases in the second trimester of pregnancy, in the period preceding the development of preterm delivery \[[@B10]\]. The increased concentration of I-TAC and MCP-4 was shown in children, who were born after preterm labor, membrane rupture, placental abruption, and cervical insufficiency \[[@B15]\]. These complications are likely to lead to fetal inflammatory response. In our study we confirmed that only I-TAC might play a role in predicting preterm delivery.

The concentrations of two studied chemokines, that is, MIP-3*α* and TARC, were higher in the groups of preterm labor and those who delivered at term as compared with false preterm labor. Previous studies also showed increased MIP-3*α* concentration during spontaneous labor at term and preterm pregnancies, what suggests its participation in the pathogenesis of childbirth. However, these two chemokines were also shown to be increased during infection \[[@B3], [@B16]\]. It gives the assumption that MIP-3*α* and TARC might be involved in the inflammatory process and be potential markers of silent inflammation during pregnancy.

The concentration of HCC-4 is significantly different between three studied groups---the concentration was the highest in the group of false preterm labor, lower in preterm births, and the lowest in term pregnancies. In previous studies, increased HCC-4 was related to preeclampsia, fetal growth restriction \[[@B17]\], and term births \[[@B18]\]. Higher concentration of HCC-4 was also demonstrated in proliferative endometrium than in atrophic endometrium \[[@B19]\]. This might indicate that chemokines do not only participate in the inflammatory process, but also affect other processes.

When we tested the concentration of total GRO, which consisted of three subunits GRO*α*/CXCL1, GRO*β*/CXCL2, and GRO*γ*/CXCL3, we found a significantly lower concentration in both preterm labor and false preterm labor as compared to natural term delivery. In one of the previous studies only GRO*α* subunit was tested in amniotic fluid and higher concentrations of this chemokine had been found during infection \[[@B20]\]. This relationship was not confirmed in a later study \[[@B21]\]. It is not known what might be the cause of decreased levels of certain chemokines in the group of preterm deliveries. It is possible that lower concentration may predispose to infection and chorioamnionitis, which seems to be a potential cause of premature birth \[[@B14]\]. It is necessary to perform further studies to investigate the possible role of these chemokines in premature childbirth.

It has been shown that chemokines could be potential markers of preterm delivery and might play a role in the pathology of premature delivery. Despite negative clinical and laboratory parameters of infection, we cannot rule out silent chorioamnionitis, which can affect the concentration of chemokines. We do not know whether the change of concentration of chemokines was associated with latent infection or the mechanism of labor. Further studies are required to determine the exact role of chemokines in preterm birth.
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###### 

Clinical characteristic of the patients.

  --------------------------------------------------------------------------------------------------------------
                                                       Group I\         Group II\              Group III\
                                                       preterm labor\   false preterm labor\   births at term\
                                                       (*n* = 62)       (*n* = 47)             (*n* = 28)
  ---------------------------------------------------- ---------------- ---------------------- -----------------
  Maternal age\                                        28.17 ± 6.39     28.74 ± 5.54           27.73 ± 4.15
  (mean ± SD)                                                                                  

  Number of pregnancies\                               2.032 ± 1.47     1.738 ± 1.01           1.679 ± 0.77
  (mean ± SD)                                                                                  

  Gestational age at collecting of samples in weeks\   29.97 ± 3.76     31.98 ± 3.34           39.25 ± 1.74
  (mean ± SD)                                                                                  

  Gestational age at birth in weeks\                   31.45 ± 3.65     39 ± 1.57              39.68 ± 1.57
  (mean ± SD)                                                                                  

  Body mass of newborn in grams\                       1866 ± 745       3143 ± 580.7           3556 ± 447.4
  (mean ± SD)                                                                                  

  Present body mass in kg\                             66.69 ± 11.82    70.23 ± 13.63          77.14 ± 11.29
  (mean ± SD)                                                                                  

  Body mass before pregnancy in kg\                    58.43 ± 9.98     60.58 ± 15.38          61.35 ± 9.59
  (mean ± SD)                                                                                  
  --------------------------------------------------------------------------------------------------------------

###### 

Concentration of chemokines in maternal sera.

  ---------------------------------------------------------------------------------------------------------------------------------------
                              Group I---\             Group II---\            Group III---\           *P* value\*    Dunn\'s test\*\*\*
                              preterm labor\          false preterm labor\    births at term\                        
                              *n* = 62                *n* = 47                *n* = 28                               
  --------------------------- ----------------------- ----------------------- ----------------------- -------------- --------------------
  6Ckine                      11539 (2713--77761)     12543 (3226--39407)     13199 (3328--74956)     0.47            

  Axl                         1306 (529.5--7509)      1389 (601.4--3074)      1278 (554.9--2203)      0.96            

  BTC                         8924 (5577--32195)      8246 (5383--18495)      8754 (6103--38241)      0.4             

  CCL28                       13504 (7193--41772)     13959 (7923--78508)     14449 (9270--54187)     0.43            

  CTACK/CCL27                 3831 (1028--93251)      4138 (1006--25364)      4205 (1932--27000)      0.88            

  CXCL16                      2849 (1789--7924)       2844 (1260--13175)      2975 (1976--13875)      0.62            

  ENA-78/CXCL5                2894 (380.8--16116)     2728 (799.4--19843)     3999 (1187--12908)      0.06            

  Eotaxin-3                   4545 (2229--18529)      4269 (1507--23502)      4845 (3239--19933)      0.28            

  GCP-2                       709.7 (132.1--2507)     743.8 (190--1841)       649.8 (90.1--1334)      0.35            

  GRO *α*. *β*. *γ*/CXCL1.\   522.6 (351.4--1187)     464.2 (350.7--891.9)    662.7 (485.1--1686)     \<0.0001\*\*   II-III\
  CXCL2. CXCL3                                                                                                       I--III

  HCC-1/CCL14                 1246 (394.7--3547)      1302 (338.9--3414)      1197 (868.4--2146)      0.59            

  HCC-4/CCL16                 849.2 (452.5--1939)     1222 (550.6--2183)      710.7 (533.9--918.3)    \<0.0001\*\*   I-II\
                                                                                                                     II-III\
                                                                                                                     I--III

  IL-9                        87505 (41779--323057)   93656 (39866--148290)   94488 (65506--175965)   0.17            

  IL-17F                      1685 (81--25311)        1204 (99.7--20224)      1335 (138.3--17388)     0.40            

  IL-18 BPa                   9087 (2811--28743)      10040 (4294--25752)     11219 (6197--41799)     0.15            

  IL-28A                      279.8 (31.9--1778)      234.6 (43.2--481)       342.3 (42.4--525.6)     0.04\*\*       II-III

  IL-29                       26560 (10546--105551)   24315 (11423--193283)   30091 (15078--131083)   0.02\*\*       II-III

  IL-31                       573 (64.8--10512)       721.5 (64.8--31428)     474.3 (84.5--33119)     0.67            

  IP-10/CXCL10                832.4 (366.8--1936)     985.3 (399.4--2013)     862.0 (524--1256)       0.08            

  I-TAC/CXCL11                55.65 (14.7--620.5)     31.60 (18.8--215.4)     48.65 (14.1--255.2)     0.005\*\*      I-II

  LIF                         2368 (378.4--4919)      2894 (814.3--4176)      2689 (1198--3678)       0.39            

  LIGHT/TNFSF14               149.8 (42.8--768.7)     149.7 (48.7--315.8)     171.4 (82.1--259.4)     0.13            

  Lymphotactin/XCL1           2814 (1457--9097)       2542 (1070--5303)       2918 (1180--4593)       0.50            

  MCP-2/CCL8                  7.9 (1.9--75.6)         6 (1.3--66.9)           11.55 (3.9--17.4)       0.08            

  MCP-3/CCL7                  54.35 (14.8--657.5)     43.7 (9.6--125)         50.7 (22--448.3)        0.36            

  MCP-4/CCL13                 120.5 (40.7--449.1)     96.3 (14.5--216.7)      118.2 (19--313.4)       0.08            

  MDC/CCL22                   3299 (778.8--9025)      3578 (152.3--9297)      3751 (1736--5840)       0.28            

  MIF                         365.5 (100.3--3214)     330.0 (105--5852)       460.9 (112.2--3347)     0.11            

  MIP-3*α*/CCL20              6.33 (1.7--51.9)        3.35 (1--8.8)           6.8 (2.2--11.6)         0.03\*\*       I-II\
                                                                                                                     II-III

  MIP-3*β*/CCL19              889.5 (400.6--3476)     860.2 (327.6--11042)    963.2 (568--11621)      0.15            

  MPIF1/CCL23                 2670 (811.7--11855)     2540 (1003--4762)       2562 (1468--13547)      0.44            

  MSP*α*                      3780 (959.8--31556)     3801 (384.2--36637)     2935 (1014--15452)      0.13            

  NAP-2/CXCL7                 221.4 (103.8--614.7)    267.6 (125.5--614.7)    197.8 (141.6--324.8)    0.016\*\*      II-III\

  OPN                         255.2 (61.9--2243)      272.5 (49.7--703.8)     376.4 (86.8--954.5)     0.24            

  PARC/CCL18                  3217 (1073--7453)       2981 (1061--6378)       3122 (1621--4999)       0.67            

  PF4                         5137 (2564--24892)      5145 (1834--13097)      5251 (1684--11418)      0.81            

  SDF-1/CXCL12                384.0 (45.7--1842)      329.5 (70.2--701.5)     333.5 (37.5--574.3)     0.52            

  TARC/CCL17                  68.40 (7.5--421.6)      39.25 (3.1--174.7)      98.25 (2.4--409.3)      0.002\*\*      I-II\
                                                                                                                     II-III

  TECK/CCL25                  24077 (5484--52685)     22457 (5431--73659)     29067 (11315--41058)    0.0047\*\*     II-III

  TSLP                        487.7 (174.1--4804)     395.2 (103.1--7183)     500.9 (108.6--2503)     0.33            
  ---------------------------------------------------------------------------------------------------------------------------------------

 \**P* value for Kruskal-Wallis test.

\*\*Statistically significant value of less than 0.05.

\*\*\*Pairs of groups for which there are statistically significant differences (significance level 0.05).

###### 

Diagnostic values of chemokines.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
             Threshold value\   Sensitivity   95% CI for sensitivity   Specificity   95% CI for specificity   AUC    95% CI         Std. error   *P* value
             (pg/mL)                                                                                                                             
  ---------- ------------------ ------------- ------------------------ ------------- ------------------------ ------ -------------- ------------ -----------
  HCC-4      \<1285             73.77         60.93 to 84.20           44.68         30.17 to 59.88           0.64   0.53 to 0.74   0.05         0.013

  I-TAC      \>33.35            73.33         60.34 to 83.93           56.10         39.75 to 71.53           0.68   0.58 to 0.79   0.05         0.002

  MIP-3*α*   \>3.60             73.68         56.90 to 86.60           50.00         21.09 to 78.91           0.73   0.57 to 0.88   0.08         0.019

  TARC       \>44.10            75.00         62.14 to 85.28           56.82         41.03 to 71.65           0.67   0.56 to 0.77   0.05         0.003
  ----------------------------------------------------------------------------------------------------------------------------------------------------------
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